Treatment with PBI-4050 may be a safe and effective therapy for patients with idiopathic pulmonary fibrosis (IPF), according to preliminary results from a Phase 2 clinical trial developed by ProMetic Life Sciences. The study (NCT02538536) has enrolled 40 IPF patients at six different sites in Canada to…
Family members of idiopathic pulmonary fibrosis (IPF) patients across generations — their children and grandchildren — recently came together in London recently to sing an emotional rendition of Rachel Platten’s hit “Fight Song,” part of a global campaign (#fightsongchallenge) to promote disease awareness. The campaign encourages IPF patients and their…
iBio, a developer of plant-based biotechnology, has announced the completion of expanded product development capacity at its subsidiary, iBio CMO, jointly owned with affiliates of Eastern Capital, for the production of pharmaceutical proteins in hydroponically-grown green plants and the large-scale manufacture of biological pharmaceutical products. iBio is…
Bristol-Myers Squibb has acquired exclusive worldwide rights to Nitto Denko’s antifibrotic drug development efforts with siRNA molecules. In addition to the Japanese company’s lead compound ND-L02-s0201, currently in a Phase 1b clinical trial (NCT02227459) for advanced liver fibrosis, the agreement gives Bristol-Myers the right to obtain licenses for other…
Australian and German companies, AdAlta and XL-protein, have entered into a collaboration to create a long-acting form of AdAlta’s AD-114, an antibody-based treatment for idiopathic pulmonary fibrosis (IPF) and other fibrotic conditions. According to the agreement, XL-protein will contribute with their PASylation technology, attaching a string of amino acids that…
Windtree Therapeutics recently presented preclinical data supporting the potential effectiveness of its KL4 surfactant against acute and chronic lung injury and fibrosis induced by exposure to radiation. The data were presented at the 62nd Radiation Research Society (RRS) Annual Meeting, that took place in Hawaii in October. KL4 is a synthetic, peptide-containing surfactant structurally similar to the…
Jordan Howard, the lead rusher for the Chicago Bears football team whose father died of pulmonary fibrosis (PF), will announced his intent to be a PF advocate and supporter of efforts to better treat and cure the disease today at the 2016 Pulmonary Fibrosis Foundation (PFF) Volunteer Meeting in Chicago. Howard’s father, Dr. Reginald…
An extract from an earthworm reduced inflammation and fibrosis in the lungs of mice exposed to silica, acting through known antioxidant and anti-inflammatory molecular pathways. The findings suggest the extract could be explored as a potential drug therapy for silicosis. The study, “Earthworm extract attenuates silica-induced pulmonary…
Inhibiting PARP-1 protein expression eased several symptoms of lung fibrosis in a mice model of the disease. These results suggest that PARP-1 inhibitors may carry therapeutic potential for patients with idiopathic pulmonary fibrosis (IPF). The study, “HYDAMTIQ, a selective PARP-1 inhibitor, improves bleomycin-induced lung fibrosis by dampening the TGF-β/SMAD signalling…
Mice that produce excessive amounts of an anticoagulant factor are somewhat protected against pulmonary fibrosis development, a finding that highlights the possibility of manipulating natural anti-clotting proteins in the fight against lung fibrosis. Experiments showed that high levels of the anticoagulant protein C caused fewer macrophage inflammatory cells to move…
Get regular updates to your inbox.
